Skip to content

Author

L. Vandevrede

6 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

When Is Amyloid Really Cleared? Substantial Discordance Between Centiloid Quantification and Visual Reads of Amyloid PET after Amyloid-Targeting Therapy

Amyloid-targeting therapies (ATTs) substantially reduce amyloid PET signal and slow clinical decline in early symptomatic Alzheimer disease. As ATTs enter clinical practice, PET may assess target engagement and guide treatment management, but there is no consensus on how to measure treatment-related amyloid clearance (...

R. la Joie, M. Lin, Y. Wang et al. · 0 citations
#small language model Open access Nov 2026

Predicting ARIA incidence due to anti-amyloid therapy for Alzheimer’s disease with multimodal risk modeling frameworks

A framework combining multimodal foundation model architectures (imaging, tabular, vision-language) with ARIA-specific design choices, including prediction heads separating ARIA-E and ARIA-H, severity grading, time-to-event modeling, and APOE-stratified monitoring decisions are proposed, validated through real-world ho...

Jin-Chi Wei, Evan Bloch, Michael Romano et al. · 0 citations
Oct 2026

Quick Conclusions From Slowed Saccades: When Progressive Supranuclear Palsy Overshadows Lewy Body Disease

Antemortem prediction of dementia-causing neurodegenerative disease is challenging, in part due to the frequency of co-occurring diseases. Etiologic diagnosis may be aided by the identification of highly specific clinical features or available biomarkers. Here we present an educational case of an individual with a prim...

D. L. Fischer, M. Sanderson-Cimino, W. Seeley et al. · 0 citations
Open access Oct 2026

Large-scale cerebrospinal fluid proteomics identifies diagnostic biomarker candidates across the clinico-pathological continuum of frontotemporal lobar degeneration

Frontotemporal lobar degeneration (FTLD), predominantly comprised of tau and TDP-43 proteinopathies, is a common cause of early-onset dementia. Biomarkers that reliably classify FTLD subtypes are limited, thereby hindering in-vivo diagnosis and clinical trial stratification. We conducted large-scale, multi-platform cer...

R. Saloner, L. Cornelis, Joshua Downer et al. · 0 citations
Open access Aug 2026

Arterial Spin‐Labeling MRI at the Cortical‐CSF Interface: A Novel Biomarker in Alzheimer Disease

ASL‐derived IF‐perfusion is reduced in AD and may represent a promising imaging marker of altered CSF‐adjacent water transport physiology and further validation against established biomarkers of CSF dynamics and clearance pathways is warranted.

Mona Asghariahmadabad, P. Metanat, Michael Thomas et al. · 0 citations
#protein folding Open access Aug 2026

Cerebrospinal fluid YWHAG:NPTX2 ratio predicts clinical severity and future phenoconversion in frontotemporal lobar degeneration

Frontotemporal lobar degeneration (FTLD) is a common cause of early-onset dementias marked by progressive declines in behavior, cognition, and/or movement. FTLD neuropathologies, including TDP-43 proteinopathies and primary tauopathies, do not have reliable fluid biomarkers for in-vivo diagnosis nor biomarkers that dir...

H. Oh, J. Downer, Connor D. Dietz et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.